| Literature DB >> 27188536 |
Peyman Eivazy1,2, Fatemeh Atyabi3, Farhad Jadidi-Niaragh4, Leili Aghebati Maleki2, Abolfazl Miahipour5, Jalal Abdolalizadeh1, Mehdi Yousefi2,6.
Abstract
High-mobility group protein two (HMGA2), a nonhistone nuclear-binding protein and its downregulators; vimentin, matrix metallopeptidase-9 (MMP-9), and E-cadherin are shown to contribute to tumor progression and metastasis. Thus, in this study, we checked simultaneous delivery of HMGA-2 siRNA and the anticancer drug doxorubicin to enhance the anticancer treatment effects. For this purpose, we used MTT assay and real-time polymerase chain reaction (RT-PCR). Our results showed that dual delivery of Dox and HMGA-2 siRNA by trimethyl chitosan (TMC) significantly inhibited breast cancer cells growth. Additionally, the delivery of siRNA significantly silenced HMGA-2, vimentin, and MMP9 mRNAs, but led to overexpression of E-cadherin mRNA.Entities:
Keywords: Breast cancer; HMGA2; nanoparticle; therapy
Mesh:
Substances:
Year: 2016 PMID: 27188536 DOI: 10.1080/21691401.2016.1185727
Source DB: PubMed Journal: Artif Cells Nanomed Biotechnol ISSN: 2169-1401 Impact factor: 5.678